Tammy Cornelius
Primary Care · Cullman, ALNPI 1366765232
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,929 of the $8,054 with a category attached, or 61.2%. 40 manufacturers reported payments, led by Medtronic at 43.4% of the total. Reporting peaked in 2022 at $2,931 and has fallen 50.2% since, to $1,461 in 2025. Among primary care clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 296 payments — averaging $27.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- AbbVie$847
- AstraZeneca$573
- Novo Nordisk$466
- GSK$328
- Amarin Pharma, Inc.$244
- plus $2K from 34 others
What the payments were for
- Speaking & faculty fees$3,12539%
- Food & beverage$4,92961%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 30 | $3,495 |
| AbbVie | 55 | $847 |
| AstraZeneca | 35 | $573 |
| Novo Nordisk | 25 | $466 |
| GSK | 21 | $328 |
| Amarin Pharma, Inc. | 16 | $244 |
| Pfizer | 12 | $224 |
| Lilly USA, LLC | 11 | $195 |
| Amgen | 9 | $183 |
| Novartis | 8 | $152 |
| Exact Sciences | 8 | $148 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $135 |
| Dexcom, Inc. | 6 | $111 |
| Bayer | 5 | $95 |
| Astellas Pharma US Inc | 5 | $89 |
| Merck | 4 | $69 |
| Lundbeck LLC | 4 | $69 |
| Boehringer Ingelheim | 3 | $59 |
| Alnylam Pharmaceuticals Inc. | 1 | $56 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Shield Therapeutics Inc | 2 | $41 |
| Eisai Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Johnson & Johnson | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Sanofi | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $23 |
| Biogen | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Abbott | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Hartmann USA, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $13 |
| BETA Bionics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$2,200
- Minimed 770G System$925
How this compares
$8,054 in reported general payments places this provider in the 90th percentile of 159 primary care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 126 | $115,401 |
| FarxigaDapagliflozin Propanediol | 94 | $99,284 |
| OzempicSemaglutide | 65 | $83,026 |
| TrulicityDulaglutide | 57 | $74,555 |
| Tresiba Flextouch U-200Insulin Degludec | 65 | $72,193 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $49,085 |
| MounjaroTirzepatide | 44 | $46,484 |
| RybelsusSemaglutide | 30 | $45,212 |
| JanuviaSitagliptin Phosphate | 30 | $34,665 |
| MyrbetriqMirabegron | 42 | $33,126 |
| XareltoRivaroxaban | 25 | $23,961 |
| EliquisApixaban | 22 | $21,090 |
| HumalogInsulin Lispro | 58 | $18,797 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $17,874 |
| RexultiBrexpiprazole | 12 | $17,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humalog Mix 75-25 | $195 | $143,389173 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $466 | $132,269110 claims |
| Boehringer IngelheimJardiance | $59 | $115,401126 claims |
| AstraZenecaFarxiga | $573 | $99,28494 claims |
| GSKTrelegy Ellipta | $328 | $49,08545 claims |
| MerckJanuvia | $69 | $34,66530 claims |
| Astellas Pharma US IncMyrbetriq | $89 | $33,12642 claims |
| Johnson & JohnsonXarelto | $34 | $23,96125 claims |
| PfizerEliquis | $224 | $21,09022 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $20 | $17,70312 claims |
| Sanofi-aventis U.S. LLCLantus | $38 | $4,41224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 159 primary care providers in Alabama.
Other primary care in Cullman
- Keith MatthewsOpelika$20K
- Troy HendersonFultondale$18K
- April TateDothan$16K
- Brandy McGrawMobile$14K
- Cleo ValdezHuntsville$14K
- Larissa RobinsonJasper$11K
- Jamie GhrigsbyMoulton$9K
- Josh WarrenBirmingham$9K
- Amber NelsonHoover$9K
- Valerie ZiemanFoley$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.